Navigation Links
Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
Date:6/29/2010

HARBIN, China, June 29 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company plans to launch a new biopharmaceutical product, Ginseng and Deer Antler Extract in August 2010. Renhuang estimates that the new product will generate revenues of RMB 3.0 million (approximately $441,000) in fiscal year 2010.

Ginseng and Deer Antler Extract are popular Chinese medicines and have been used for centuries to nourish the blood and the kidneys, restore the body's energy and increase endurance. It is also believed that the compounds work together to promote longevity. Moreover, TCM practitioners employ the ingredients in Renhuang's Ginseng and Deer Antler Extract to balance the body's "Qi" or vital life force. Renhuang brings the advantages of its GMP-certified modern manufacturing processes and state of the art research and development to this trusted remedy.

"We are excited to further expand our product portfolio with another new high-quality, all-natural bio-pharmaceutical product -- our Ginseng and Deer Antler Extract," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "This is our third new product announcement in 2010, following the successful launch of Qing Re Jie Du Oral Liquid and the recent development of Compound Schisandra Tablets. These new products highlight our R&D strength and our ability to continually cater to the needs of the rapidly expanding Chinese bio-pharmaceutical market. Since there is no clear market leader in this segment, we expect our Ginseng and Deer Antler Extract to be a positive contributor to our revenue growth. We will support this promising new product with a significant marketing effort and aim to establish it as a product of choice for TCM practitioners and consumers."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to expand its Ginseng and Deer Antler Extract product and achieve its estimated sales estimates, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-8260-2162
     Email: ir@renhuang.com

    CCG Investor Relations:
     Mr. Mark Collinson, Partner
     Phone: +1-310-954-1343 (Los Angeles)
     Email: mark.collinson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Announces Fiscal Year 2010 Guidance
2. Renhuang Announces Price Increase on Shengmai Granules
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
5. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
6. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
7. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
11. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology:
(Date:2/10/2016)... Denver, Colorado (PRWEB) , ... February 10, 2016 , ... ... now, but cannabis enthusiasts in the state still face a lot of restrictions as ... “retail marijuana is intended for private, personal use” and that cannabis “may not be ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... A new ... for Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, ... Montague, a 2003 graduate of FHU and the creator of GO! Camp, has been ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/10/2016)... Franklin, TN (PRWEB) , ... February 09, 2016 ... ... related to sports concussion, yet the cause of injury may be one of ... This two-day advanced PT Continuing Education Course , Mastering Rehab Solutions ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Steven Douglas ... Taste of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural ... and guests alike. This year the event will be held in a new, more ...
Breaking Medicine News(10 mins):